PIK3CG and T-cell non-Hodgkin lymphoma: Actually, the efficacy of rapalogs and dual PI3K/mTOR inhibitors have been largely proven in vitro in T-cell lymphoma [57, 58] but, despite these results, few clinical trials in CTCLs are ongoing (http://www.tcllfoundation.org/current-clinical-trials.